




























Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Gilles, F., Gressens, P., Dammann, O., & Leviton, A. (2018). Hypoxia-ischemia is not an antecedent of most
preterm brain damage: the illusion of validity. Developmental Medicine and Child Neurology, 120-125. DOI:
10.1111/dmcn.13483
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 30. Jun. 2018
DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY REVIEW
Hypoxia–ischemia is not an antecedent of most preterm brain
damage: the illusion of validity
FLOYD GILLES1 | PIERRE GRESSENS2,3,4 | OLAF DAMMANN5,6 | ALAN LEVITON7
1 Children’s Hospital Los Angeles, Los Angeles, CA, USA. 2 Inserm, U1141, Ho^pital Robert Debre, Paris; 3 Univ Paris Diderot, Sorbonne Paris Cite, UMRS 1141, Paris,
France. 4 Centre for the Developing Brain, Division of Imaging Sciences and Biomedical Engineering, KCL, St. Thomas’ Hospital, London, UK. 5 Tufts University School
of Medicine, Boston, MA, USA. 6 Hannover Medical School, Hannover, Germany. 7 Boston Children’s Hospital and Harvard Medical School, Boston, MA, USA.
Correspondence to Floyd Gilles at Department of Pathology, Children’s Hospital Los Angeles, MS43, 4650 Sunset Blvd, Los Angeles, CA 90027, USA. E-mail: fgilles@chla.usc.edu
This article is commented on by Paneth on page 115 of this issue.
The legal statement for this article was updated from CC-BY-NC to CC-BY on 02 March 2018 after online publication.
PUBLICATION DATA
Accepted for publication 6th April 2017.
Published online 28th June 2017.
ABBREVIATIONS
BOOST Benefits of Oxygen Saturation
Targeting
COT Canadian Oxygen Trial
SUPPORT Surfactant, Positive Pressure,
and Oxygenation Randomized
Trial
Brain injury in preterm newborn infants is often attributed to hypoxia–ischemia even when
neither hypoxia nor ischemia is documented, and many causative speculations are based on
the same assumption. We review human and animal study contributions with their strengths
and limitations, and conclude that – despite all the work done in human fetal neuropathology
and developmental models in animals – the evidence remains unconvincing that hypoxemia,
in the fetus or newborn infant, contributes appreciably to any encephalopathy of prematurity.
Giving an inappropriate causal name to a disorder potentially limits the options for change,
should our understanding of the etiologies advance. The only observationally-based title we
think appropriate is ‘encephalopathy of prematurity’. Future pathophysiological research
should probably include appropriately designed epidemiology studies, highly active develop-
mental processes, infection and other inflammatory stimuli, the immature immune system,
long chain fatty acids and their transporters, and growth (neurotrophic) factors.
INTRODUCTION
Disorders identified by an etiological name
Despite a complete lack of evidence, encephalopathy of
prematurity has been attributed to hypoxia (ischemia).
Physicians seem to rely on a limited number of heuristic
principles, which reduce the complex tasks of assessing
probabilities and predicting values to simpler judgmental
operations. These heuristics sometimes lead to severe and
systemic errors for which Tversky and Kahneman coined
the term ‘The illusion of validity.’1 For instance, attribut-
ing a single cause to a disease should serve a purpose.
Applying that attribution to the disease name, however,
probably does not serve any useful purpose, as it is likely
overly simplistic and potentially limits the options for
change when our understanding of the etiologies advances.
To avoid errors associated with using an inappropriate
causal label, some have suggested that the more general
descriptive term ‘neonatal encephalopathy’ or ‘newborn
encephalopathy’ should replace hypoxic–ischemic
encephalopathy,2 or have used the term ‘encephalopathy of
prematurity,’3 but have not turned away from the original
term ‘hypoxic–ischemic encephalopathy.’4 Given the term
‘hypoxic–ischemic encephalopathy’, we are not surprised
when most neonatal animal studies use some form of
asphyxia. We are not denying that infants born very-low-
birthweight and preterm are at risk of multiple neurologi-
cal dysfunctions, multiple abnormalities on imaging, or
multiple abnormalities at autopsy. We are suggesting that
while hypoxia may be behind some abnormalities, most are
the result of multiple contributions and consequently
experimental work be directed toward other etiologies as
well.
In this review, we focus on the encephalopathies seen in
newborn infants born preterm, lesions attributed to
hypoxia or hypoxia–ischemia, animal studies with their
strengths and limitations, and conclude with the design of
an ideal epidemiological study.
Why is brain injury so much more common in preterm
newborn infants than in those born near term?
The association between very preterm birth and subse-
quent neurological deficit is attributable to seven factors
and while these vulnerabilities may interact with hypoxia
and they may also interact with many other antecedents.
First, some immature brain vulnerability can be attributed
to highly active developmental processes such as dendritic
or axonal growth (particularly growth cone proliferation),
vasculogenesis, myelinogenesis, and angiogenesis.5 Second,
a paucity of essential long chain fatty acids6 or appropriate
fatty acid transporters such as Mfsd2a can further increase
vulnerability. Third, newborn infants born very preterm
appear to be unable to synthesize some growth factors in
the amounts needed for normal development.7 Fourth, a
low supply of such growth factors may be inadequate to
protect against adversity.8,9 Fifth, the infant born preterm
is exposed to a host of potentially harmful exposures
before, during, and after delivery, with many differing from
those experienced by infants born close to term.5 Sixth,
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immature immune system stimulation potentially results in
an overly intense inflammatory response that is likely sus-
tained for some time.10 Seventh, inflammation diminishes
the blood–brain barrier of newborn infants born very
preterm.11
HYPOXIA–ISCHEMIA
The term ‘hypoxia–ischemia’ conflates two very different
physiologies, and we choose to separate them.
Hypoxia
Hypoxia, or more appropriately hypoxemia, if sufficiently
prolonged induces energy failure, and is associated with
loss of neuronal function, much less in neonatal than in
adult animals, and least in animals born preterm.12 The
very preterm brain normally has much lower aerobic
requirements than the brain at term.13 But, to the best of
our knowledge, hypoxia alone, with sustained cerebral per-
fusion, has not been shown to cause brain lesions, either in
preterm, term, or adult human or in experimental animal
studies. While certain selective neuronal losses in adult
brain have been attributed to hypoxia such specificity has
yet to be verified.
Ischemia
Ischemia, a general or focal restriction in tissue blood sup-
ply, also induces energy failure, but is far more complex
than hypoxia in that it also diminishes blood component
availability, and limits brain metabolic waste removal.
Often this is due to systemic hypotension or cerebral vas-
cular occlusion. Experimentally, hypotension is very
important in producing lesions after umbilical artery occlu-
sion.14,15 Further, hypocapnia seems to increase the risk
the risk of cerebral palsy (CP),16 presumably by attenuating
local cerebral vascular supply. In newborn infants born
preterm, however, hypotension does not appear to account
for any brain ultrasound abnormality within the first
10 days,17 but this ‘negative finding’ has limited value
because ultrasound scans do not provide an adequate view
of cortical arterial borderzone regions.
HUMAN STUDIES
Because even mild hyperoxia appears to increase the risk of
retinopathy of prematurity, neonatologists want to minimize
the occurrence of hyperoxia, while at the same time avoiding
levels of hypoxia they think might injure the brain. Three
large, multicenter clinical trials were organized in an effort
to find the optimum pulse oximeter oxygen saturation
(SpO2) target ranges for infants born extremely preterm.
18–
20 All three compared ‘restricted’ oxygen exposure (defined
as an oxygen saturation [SpO2] in the 85%–89% range) to
liberal exposure (SpO2, 91%–95%) among infants born
extremely preterm (<28wks’ gestation at birth).
The Surfactant, Positive Pressure, and Oxygenation Ran-
domized Trial (SUPPORT) was conducted in the United
States (n=1316)18 while the Canadian Oxygen Trial (COT)
was a multinational trial enrolling newborn infants in both
Canada and the United States (n=1201).19 The Benefits of
Oxygen Saturation Targeting II (BOOST II) trials included
three trials conducted in the United Kingdom (n=973), Aus-
tralia (n=1135), and New Zealand (n=340).20 After publica-
tion of the first results from the SUPPORT trial,18 the data
monitoring committees of the similar BOOST II trials in
Australia and the United Kingdom terminated recruitment
early but the children enrolled in these studies continued to
be followed. This allowed the results from the Australian
and United Kingdom components to be combined with
results of the New Zealand component (of the BOOST II
trial), which had already completed recruitment.
All three studies, the SUPPORT,18 BOOST II trials (New
Zealand component only [BOOST-NZ]),20 and COT,19
assessed death or disability before postnatal age 18 to
24 months as a primary outcome. In none of the trials was the
risk of death or disability significantly elevated (SUPPORT:
risk ratio=1.1; 0.9–1.3; COT: risk ratio=1.04; 0.9–1.2;
BOOST-NZ: risk ratio=0.9; 0.7–1.1). Combining all three
studies showed neither increased nor decreased risk of death or
disability by age 18 to 24 months (risk ratio=1.02; 0.9–1.1).21
‘Death or disability’ as the primary outcome is difficult
for those of us who do not favor composites of (vastly) dif-
ferent endpoints. This composite is often justified because
death and disability are seen as competing risks: you have
to survive to be at risk of disability. So why not first evalu-
ate the risk of death, and then evaluate among survivors
the risk of indicators of brain injury?
The COT report did not include death alone as an indi-
vidual outcome, but the SUPPORT and BOOST trials
did. Although neither the SUPPORT nor the BOOST tri-
als alone found that children with restricted oxygen expo-
sure were at increased risk of early death, combining data
from these two trials allowed the increased risk of death
before discharge associated with restricted oxygen exposure
to achieve statistical significance (risk ratio=1.2; 95% confi-
dence interval: 1.03–1.4).21
Although none of the three studies had an indicator of
impaired neurodevelopment as a primary outcome, all
included a Gross Motor Function Classification System
(GMFCS) level of II or higher as a secondary outcome.
The GMFCS was developed to classify the motor function
of children who have a diagnosis of CP. It was not
intended for use among children who are not thought to
have CP. GMFCS level I is defined as able to walk indoors
and outdoors and climb stairs without using hands for sup-
port, and able to run and jump. The earlier in the 18- to
What this paper adds
• Fetal hypoxemia is rarely documented in brain injury studies.
• Animal studies fail to consider human–animal fetal anatomical differences.
• Putative treatments from animal models have not found clinical use.
• Observational studies constitute the only approach to etiological understanding.
• No convincing evidence yet that hypoxemia injures preterm brain. Encephalo-
pathy of prematurity is preferable to hypoxia-ischemia as a term for this dis-
order.
• Encephalopathy of prematurity is preferable to hypoxia-ischemia as a term
for this disorder.
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24-month age range, the greater the likelihood the child
will be identified as having a GMFCS level at or above II,
regardless of whether or not the child will develop cerebral
palsy. Indeed, the developers of the GMFCS who assessed
children at a mean age of 19 months suggested that ‘there
is a need for reclassification at age 2 or older as more clini-
cal information becomes available.22
Consequently, the likelihood of misclassification deserves
consideration as we assess the quality of these studies.
Indeed, the authors of the meta-analysis concluded, ‘Using
the Grades of Recommendation, Assessment, Develop-
ment, and Evaluation (GRADE) criteria, we found that the
quality of evidence for these outcomes (including neurode-
velopmental outcomes) was moderate to low.21
With this caveat, the risk of a GMFCS level at or above
II was not significantly elevated in the SUPPORT trial
(risk ratio=1.2; 0.7–2.1), the COT trial (risk ratio=0.97;
0.6–1.67), or the BOOST-NZ trial (risk ratio=0.7; 0.2–
2.2). In a meta-analysis combining all three studies, the
risk ratio was very close to 1.0 (risk ratio=1.03; 0.7–1.5).21
Thus, we can say, given the limited evidence available, that
hypoxia at levels clinicians can tolerate does not appear to
increase the risk of motor limitation at 18 to 24 months.
This statement is especially important in light of evidence
that the restricted levels of oxygen appear to increase the
risk of death. Death? Yes. Disability? No.
The only observational study that evaluated the hypothe-
sis that oxygen lack is an antecedent of white matter injury,
CP, low Bayley Scales, and microcephaly in newborn
infants born extremely preterm found that every one of the
five blood gas derangements during the first three postna-
tal days (hypoxemia, hyperoxemia, hypocapnia, hypercap-
nia, and acidemia) was associated with multiple indicators
of brain injury.23 The patterns of associations varied con-
siderably and not necessarily in a cohesive manner. Rather
than inferring that the blood gas derangements caused the
brain injury, a more plausible interpretation is that the
multiple derangements are indicators of immaturity/vulner-
ability and illness severity.
In light of these reports, we draw the inference that no doc-
umentation has yet been provided that hypoxia contributes to
brain injury in very preterm newborn infants, even when such
levels of hypoxia appear to increase the risk of death.
FETUS
In this day of evidence-based medicine, one expects that
the clinical diagnosis of ‘hypoxic encephalopathy’ implies
that there has been a documented sufficiently long and
severe hypoxic exposure. However, the entity in
newborn infants born at term labeled ‘hypoxic–ischemic
encephalopathy’ often does not follow hypoxic–ischemic
exposures.24,25
Moreover, the embryo and fetus develop in a markedly
hypoxic environment,26 with oxygen concentrations of
0.076 to 7.6 mmHg compared to those in adults of 11.4 to
53.2 mmHg,27 and local hypoxic regions exist within
embryonic and fetal brain, heart, and mesenchyme,
apparently promoting embryonic and fetal vascularization
and organogenesis.28
Blood pressure and flow relationships in newborn infants
born preterm differ markedly from those in adults. Three
fetal circulation shunts, ductus venosus, foramen ovale, and
ductus arteriosus, permit oxygenated fetal blood to bypass
liver and lungs and enter the left heart, but still only half
the blood is oxygenated during one fetal circulation cycle.
Consequently, adult concepts cannot be automatically
applied to the preterm fetus. In fetal lambs, arterial pres-
sure is low and systemic arterial blood gas tensions are
asphyxial by adult standards. Cerebral vascular resistance
declines between mid-gestation and term.29
LESIONS ATTRIBUTED TO HYPOXIA-ISCHEMIA
Neuronal death – regardless of where along the axis
from apoptosis through necrosis, necroptosis,30,31 and
pyroptosis – by itself gives no clue about etiology, except
perhaps when occurring in borderzone regions, in part
because neuronal death results from many different
metabolic, vascular, or inflammatory derangements, each
often the consequence of multiple different antecedents.
The numerous morphological lesions attributed to
hypoxia-ischemia over the last 60 years include the follow-
ing: hemorrhage in many brain locations; edema; endothe-
lial injury; necroses in many locations including gray
matter and white matter; infarct; white matter gliosis; atro-
phies; cysts in many locations; myelination delay; ventricu-
lomegaly; hydranencephaly; and finally, malformation.32–34
Thus, the term hypoxic–ischemic encephalopathy fails to
predict specific structural outcomes. The isolated occur-
rence of each entity can be attributed to the same etiology
only if other phenomena (e.g. specific time and specific
location) are also important; if they are, then the entity is
really multifactorial.
ANIMAL MODELS ARE NEEDED TO UNDERSTAND
PRETERM HUMAN BRAIN ABNORMALITIES
Good translational research requires suitable animal mod-
els, yet interspecies differences limit the relevance of mod-
els mimicking human pathophysiology. In fact, some
students of animal models are not sure how well animal
models in general match human cancer, cerebral infarcts,
stroke therapies, microglia, and complex human behavioral
disorders. Common deficits have been poor methodologi-
cal quality,35 low statistical power, poor statistical analyses,
and lack of blinding and randomization. Investigators of
developmental brain injury have focused on cerebral matu-
ration, blood flow, metabolism, and white matter injury,
but other areas may need attention. In addition, some ani-
mal models do not resemble the human pathological
abnormality to provide therapeutic candidates. For
instance, a model producing any brain injury is not a
model of human focal white matter necrosis.36 The ideal
model replicates all aspects of the human disease being
modeled, including exposures, dysfunctions, and morphol-
ogy. Because this is rarely practicable, close approximations
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are acceptable with caveats, as long as we acknowledge
their limitations. For instance, if the effect of brain hypoxia
is being modeled, then cerebral blood flow must be held
constant and the resultant brain injury must resemble the
specific brain abnormality modeled.
Developmental differences between humans and other
mammals
Timing, opportunity window, ischemia duration, drug
dose, species, sex differences, comparable fetal develop-
mental age, and underlying diseases all need consideration
when designing and evaluating models of fetal cerebral
abnormalities.37 Unfortunately some of these characteris-
tics have been ignored. Human infants are advanced at
birth relative to rat and rabbit. Thus rat at P1 or P2 is
roughly equivalent to human at 0.45 of its fetal develop-
mental time and rat at P7 is roughly equivalent to human
at 0.60 gestation. Similarly, rabbit at E22 or E25 is
roughly equivalent to human at 0.35 gestation, at least
based on tract appearance.38 Still, these models offer
opportunities to study effects of various agents or proce-
dures on fetal brain.
Cerebral autoregulation in preterm fetuses
Term and preterm animal fetuses respond to asphyxia (the
combination of hypoxia, hypercapnia, and metabolic acido-
sis) in a qualitatively similar manner.13 Sometimes the
asphyxia does not occur in isolation. For example, umbilical
cord occlusion decreases brain oxygen availability, but it
also reduces fetal systemic blood pressure, diminishes blood
component availability, and limits brain metabolic waste
removal. Animal studies suggest that hypotension timing
during severe asphyxia influences location and magnitude
of cerebral injury, likely because of the close relationship
between fetal blood pressure maintenance and changes in
brain perfusion. Nevertheless, the concept of cerebral
autoregulation in preterm humans continues to evolve.
Anatomical differences between human and other
mammalian fetuses
Animal and human fetal differences need consideration
when designing studies. For instance, the popular sheep
fetus model has a different anatomy than the human fetus.
The sheep fetus has a longer intrathoracic inferior vena
cava, different liver position, two umbilical veins, higher
body temperature, lower hemoglobin, shorter pregnancy,
and a syndesmochorial cotyledonary placenta rather than
the human hemomonochorial placenta, all potentially
important in an experimental study. Further, unlike the
human fetus,39 the fetal sheep’s major intrauterine brain
growth spurt occurs well before birth, resulting in much
earlier cerebral myelination,40 and a much smaller brain.
Sheep also have a different cerebral blood supply with an
interposed carotid rete mirabile.41 This point is crucial
because the fetal lamb does not have a proximal internal
carotid segment. An external carotid branch supplies the
rete (composed of a bed of fine branches) interposed
between systemic and cerebral circulations, raising ques-
tions of whether sheep fetal cerebral circulation is suffi-
ciently similar to human fetal circulation to be a model of
human fetal brain circulatory abnormalities. Similar ques-
tions about the relevance to human disease need considera-
tion when interpreting results of rodent models.
SELECTED ANIMAL STUDIES
The following remarks are offered as commentary to
accompany a reading of Table SI (online supporting infor-
mation).
Baboons
The two baboon studies (Inder et al.42 and Loeliger
et al.43) were chosen to indicate that preterm birth, alone
without additional manipulation, is not benign and, in
these primates, results in cerebral injury (Table SI).
The remaining 10 models of acquired human prenatal
cerebral abnormality attributed to hypoxia in Table SI
were chosen because of their strengths and the care with
which they were executed. The researchers who used these
models considered the animal developmental stages equiva-
lent to preterm human infants, although this may be inac-
curate.38 In addition to hypoxia, these models required
occlusion of carotid, umbilical, maternal descending aorta,
or uterine arteries, thus potentially lowering cerebral blood
flow. Blinded observers were utilized in five studies. Only
one used randomization, despite the criteria for human
clinical studies requiring randomization and double blind-
ing, potentially introducing bias.44 In addition, failure to
uniformly and effectively monitor the animal’s response to
anesthesia, particularly blood pressure, poses inferential
problems. Fetal brain hypoxia degree was not evaluated,
although systemic PaO2 showed a 30 to 40 percent
decrease in two studies.44,45
Fetal sheep
We included the first sheep model (Wassink et al.46)
because it indicates that fetal umbilical artery occlusion
causes bradycardia, transient hypertension, and then
hypotension, less in younger than in more mature fetuses,
but brains were not examined. Keunen et al.’s study indi-
cates that fetal sheep at midgestation do not get neuronal
injury with 10 to 20 minutes of umbilical artery occlu-
sion,44 but Mallard et al. found that fetal sheep later in
gestation did get neuronal injury with daily microsphere
injection into the umbilical circulation.47 George et al.’s
study, furthermore, found basal ganglia, thalamic, hip-
pocampal, and medullary injury after umbilical cord occlu-
sions at roughly midgestation.48 Differences among these
studies probably reflect not only fetal age, but also differ-
ences in study design. Brain energy supplies were not mon-
itored, nor was fetal brain hypoxia tolerance measured.
Rodents
The three postnatal rat studies (Rice et al.,49 McQuillen
et al.,50 and Sizonenko et al.51) found cortical and basal
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ganglia injury with white matter necrosis, subplate neu-
ronal loss, or white matter loss after carotid occlusion and
hypoxia. The Buser et al., Drobyshevsky et al., and Derrick
et al. rabbit studies, all done at very early developmental
stages, found gray and white matter injury after maternal
descending aorta occlusion.45,52,53
Models requiring circulatory impairment
In the absence of evidence in human newborn infants born
very preterm that hypotension causes brain injury,17 the
models requiring circulatory impairment cannot be viewed
as suitable models of the preterm human fetus. Global
cerebral ischemia secondary to maternal or fetal vascular
occlusion is hardly appropriate, given what we know about
the preterm human fetus. We have included fetal mortality
rates, when reported, to show that for several of these
experiments investigators were working close to fetal
lethality. Importantly, no model suggested testable thera-
peutic interventions.
SYNTHESIS AND OUTLOOK
Hypoxia beyond the normal fetal hypoxic environment as
an antecedent has not been documented as causing injury
in the preterm fetus. The fetus has a different blood supply
as blood pressure and flow relationships differ from those
in the adult. The large number of pathological conditions
attributed to hypoxia indicates that the term ‘hypoxic
encephalopathy’ has limited predictive power. Experimen-
tal animal studies have failed to take anatomical differences
into consideration, leave much to be desired, and have not
resulted in therapeutic candidates.
Despite all studies in animals and humans, the evidence
remains unconvincing that hypoxemia, in the fetus or new-
born infant, contributes appreciably to any encephalopathy
of prematurity. Thus, the criteria for attributing perinatal
brain injury to hypoxemia have not been met.
We recommend that until evidence becomes available,
hypoxia–ischemia should not be viewed as contributing to
the occurrence of what is included under the umbrella of
‘encephalopathy of prematurity’.
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